PeDRA

Pediatric Dermatology Research Alliance

Webinars

Webinar: Using Social Media to Advance Your Career

By

Learn how to promote your science via social media channels. Featured presenters, Dr. Joel Gelfand, Dr. John Harris, and Dr. Daniel Sugai will share their experiences with social media and answer your questions live, February 10, 2021 at 5:30PM PST / 8:30PM EST.

This program is run in partnership with the Society for Pediatric Dermatology Junior Faculty/Fellows Committee.

Using Social Media to Advance Your Career with Live Q&A
Wednesday, February 10, 2021 at 5:30PM PST / 8:30PM EST

This event is for PeDRA and SPD members only – pre-registration is required.

Hosts: Jiade Yu, MD and Lisa Arkin, MD

Speakers: Joel Gelfand, MD, MSCE
John Harris, MD, PhD
Daniel Sugai, MD

register

Speakers

Joel Gelfand, MD, MSCE

Joel M. Gelfand MD MSCE is Professor of Dermatology and Epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also Vice Chair of Clinical Research, Medical Director of the Dermatology Clinical Studies Unit, and Director of the Psoriasis and Phototherapy Treatment Center. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 260 scientific publications, editorials, reviews, and text book chapters (cited over 18,000 times, H index 60) which appear in journals such as JAMA, BMJ, European Heart Journal, Annals of Rheumatic Disease, JAMA Dermatology, JAAD, and the JID. He is a past Associate Editor of Pharmacoepidemiology and Drug Safety, past Editorial Board Member of the Journal of the American Academy of Dermatology, and is currently Deputy Editor of the Journal Investigative Dermatology. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, PENN’s New Investigator Marjorie Bowman Award and the Lady Barbara Colyton’s Award for Autoimmune research, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, National Psoriasis Foundation’s (NPF)  inaugural award for scientific achievement, and is an elected member of the American Society for Clinical Investigation. He Co-Chairs the NPF’s COVID-19 task force, and is a member of the Board of Directors for the International Psoriasis Council. He is a co-author of the AAD-NPF joint guidelines of care for psoriasis. He has given over 10 named lectureships and keynote addresses including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture. He has received grant support from NIH, FDA, PCORI, the Dermatology Foundation, the American Skin Association, the NPF, and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.

    John Harris, MD, PhD

    Dr. Harris is the Chair of Dermatology, Founding Director of the Vitiligo Clinic and Research Center, and Founding Director of the Autoimmune Therapeutics Institute at UMass Medical School in Worcester, Massachusetts. He is a dermatologist and physician-scientist, caring for patients in a vitiligo specialty clinic and running a large research laboratory focused on understanding disease pathogenesis and developing new treatments. His group integrates basic, translational, and clinical research strategies to accomplish this. As a result, early clinical trials in vitiligo have shown success, and more are being developed. Finally, Dr. Harris founded Villaris Therapeutics, whose entire focus is to develop an effective, long-lasting treatment for vitiligo.

      Daniel Sugai, MD

      Dr. Daniel Sugai was born and raised on the Hawaiian island of Oahu where he studied biology and art in college at the University of Hawaii. He then went on and got his M.D. from the University of Hawaii and was Class President and President of his school’s AOA Honor Society. He completed his dermatology training in the Harvard Combined Dermatology Residency Program where he trained at Mass General Hospital/BWH/Beth Israel Deaconess Medical Center/Boston Children’s Hospital. Upon graduating from residency and passing his board certification examination, he moved to Seattle, WA and practices medical, cosmetic and surgical dermatology- seeing pediatrics and adults. He received multiple “Top Doctor” accolades including Seattle Met Magazine Top Doctor 2020. At the start of the pandemic in March/April 2020, Dr. Sugai started a YouTube channel, Instagram and TikTok to help disseminate credible science-backed skin education to the masses. It has become a “second job” and a passion of his and he enjoys connecting with people from all around the globe. 

        Webinar: Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session

        By

        Join PeDRA on Monday, January 11 at 5:30 PM PST / 8:30 PM EST. PeDRA President-Elect Anna Bruckner, MD, MSCS will give a presentation on basic biology underlying EB and recent advances in EB clinical research. Pre-registration is required. Webinar sponsored by Amryt Research Ltd.

        Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session, Sponsored by Amryt Research Ltd.
        Monday, January 11, 2021, 5:30 PM PST / 8:30 PM EST

        Speaker: Anna Bruckner, MD, MSCS

        coming soon

        Speaker

        Anna Bruckner, MD, MSCS

        Dr. Bruckner is Associate Professor of Dermatology and Pediatrics and at the University of Colorado School of Medicine and Director of Pediatric Dermatology at Children’s Hospital Colorado. She attended Northwestern University as part of the Honors Program in Medical Education, earning her MD in 1997. She completed residencies pediatrics and dermatology at the University of Colorado followed by a fellowship in pediatric dermatology at the University of California San Francisco. She maintains board-certification in dermatology and pediatric dermatology.

        Dr. Bruckner is passionate about improving outcomes and quality of life for children with skin disorders through patient care, research, education and advocacy. Her academic interests include genetic skin disorders – particularly epidermolysis bullosa (EB), vascular anomalies, atopic dermatitis, and complex patients. She is the principal investigator for the Epidermolysis Bullosa Clinical Research Consortium, a network of North American EB care centers collaborating in clinic research aimed at improving the care and outcomes for patients with EB.

        Dr. Bruckner is a founding member of the Pediatric Dermatology Research Alliance (PeDRA) and served on PeDRA’s Executive Committee until 2016. She is now the 2022 President-Elect.

          PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at info@pedraresearch.org with any questions or concerns. This webinar is being hosted by PeDRA and sponsored by Amryt Research Ltd.
          Date of preparation: December 2020. VV-MED-00552

          Webinar: EB-101 Clinical Development Update and Q&A Session

          By

          Join PeDRA on Thursday, November 12 for a sponsored webinar being hosted in partnership with Abeona Therapeutics on cutting edge clinical development updates towards the treatment of epidermolysis bullosa. The webinar will feature presentations from Jean Tang, MD, PhD (Professor of Dermatology, Stanford University Medical Center and Principal Investigator, EB-101 pivotal Phase 3 VIITAL study) and Michael Amoroso (Chief Commercial Officer, Abeona) and moderated discussion. Pre-registration is required.

          EB-101 Clinical Development Update and Q&A Session, sponsored by Abeona Therapeutics
          Thursday, November 12, 2020 8:00 AM PST / 11:00 AM EST

          Speakers: Jean Tang, MD, PhD and Michael Amoroso

          watch now

          Speakers

          Jean Tang, MD, PhD

          Professor of Dermatology, Stanford University Medical Center AND Principal Investigator, EB-101 pivotal Phase 3 VIITAL study

          Dr. Tang’s research focuses on genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. She studies new ways to treat and prevent NSMC and melanoma. Dr. Tang has led or co-led the conduct and completion of 6 investigator initiated clinical trials in BCC and EB. She received her MD/PhD from Stanford (Biophysics), completed her dermatology residency at Stanford, and then went to UCSF for a 3 year post-doc in mouse genetics, while simultaneously pursuing formal coursework in biostatistics, epidemiology, and clinical trial design in the KL2 CTSI program.

            Michael Amoroso, MBA

            Chief Commercial Officer, Abeona

            Michael Amoroso joined Abeona as Senior Vice President and Chief Commercial Officer in July 2020, bringing over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries with a focus on cell and gene therapies, and a proven track record of launching innovative drugs for rare diseases.

            Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi.

            Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.

              This webinar is being hosted by PeDRA and sponsored by Abeona Therapeutics. PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at info@pedraresearch.org with any questions or concerns.

              Series: Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children

              By

              Moderate-to-severe atopic dermatitis is associated with negative impacts on quality of life and health outcomes in all age groups, with the impact on children and families being uniquely severe. However, the rapid pace of drug development and uncertainty around novel medications may impact the shared decision-making process and lead to suboptimal treatment of many children. Thus, educating pediatric dermatologists and allergists is critical to positively affect treatment decisions and improve long-term outcomes. In addition, engaging experts in pediatric dermatology and allergy to consider what are the most important research issues in atopic dermatitis is important to direct future efforts. To address this need and help fill the gap left by canceled conferences in 2020, PeDRA is conducting a six-part educational series Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children.      

              Being hosted by distinguished faculty in pediatric dermatology and allergy/immunology, this non-CME program will include a total of six parts, including two webinars, two podcasts, and two virtual meetings/townhalls. 

              Part 1: PEDIATRIC ATOPIC DERMATITIS – New and Emerging Systemic Therapies: An Overview
              RECORDED LIVE: Tuesday, October 6, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT

              Chair: Lawrence Eichenfield, MD
              Speakers: Megha Tollefson, MD and Bob Geng, MD
              Panel: Wynnis Tom, MD and Dawn Davis, MD

              View Full Agenda

              5:15 – 5:20 – Introduction
              5:20 – 5:37 – Biologics – Overview and translation to practice
              5:37 – 5:49 – JAK-inhibitors
              5:49 – 6:01 – Mechanisms of action and allergy perspectives
              6:01 – 6:15 – Moderated discussion with audience

              Watch NOW

              Part 2: PEDIATRIC ATOPIC DERMATITIS – Algorithms of the Future
              RECORDED LIVE: Tuesday, October 13, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT

              Chair: Lawrence Eichenfield, MD
              Speakers: Dawn Davis, MD and Wynnis Tom, MD
              Panel: Megha Tollefson, MD and Bob Geng, MD

              View Full Agenda

              5:15 – 5:20 – Introduction
              5:20 – 5:32 – New topicals for moderate to severe disease
              5:32 – 5:42 – New and traditional systemics: where do they fit?
              5:42 – 6:00 – Considerations when selecting appropriate therapy for the appropriate patient
              6:00 – 6:15 – Interactive discussion on “hot” research issues in moderate to severe atopic dermatitis for pediatric dermatologists and allergists

              Watch now

              Part 3: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
              AVAILABLE NOW

              Host: Lawrence Eichenfield, MD
              Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
              Guests

              Listen here

              Part 4: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
              Tuesday, December 8, 2020 5:15 – 6:15PM PST / 8:15 – 9:15PM EST

              Host: Lawrence Eichenfield, MD
              Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
              Special Guests: Emma Guttman-Yassky, MD, PhD and Eric Simpson, MD

              Listen Here

              Part 5: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
              AVAILABLE NOW

              Host: Dawn Davis, MD
              Special Guests: Charlene Miciano and Sarah Pry

              Listen here

              Part 6: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
              Tuesday, January 5, 2021, 5:15 – 6:15PM PST / 8:15 – 9:15PM EST

              An open discussion with faculty and patient advocates in follow-up to the second podcast. Bring your questions or just listen in.

              Host: Dawn Davis, MD
              Guests: Lawrence Eichenfield, MD, Bob Geng, MD, and Wynnis Tom, MD
              Special Guests: Korey Capozza, MPH from Global Parents for Eczema Research and Wendy Smith Begolka, MBS from the National Eczema Association

              Listen here

              FACULTY

              Lawrence Eichenfield, MD

              Chair

              Professor of Dermatology and Pediatrics
              Chief, Pediatric and Adolescent Dermatology
              Vice Chair, Department of Dermatology
              University of California, San Diego and Rady Children’s Hospital, San Diego

                Bob Geng, MD

                Assistant Professor of Medicine and Pediatrics
                Divisions of Adult and Pediatric Allergy & Immunology
                Co-Director of the Allergy Asthma Foundation of America sponsored UCSD Pediatric Severe Asthma Program
                Allergy/Immunology Director of the Multidisciplinary Atopic Dermatitis Program
                University of California, San Diego and Rady Children’s Hospital, San Diego

                  Dawn Davis, MD

                  Professor of Dermatology and Pediatrics
                  Division Chair, Clinical Dermatology
                  Director, Section of Pediatric Dermatology
                  Mayo Clinic Rochester

                    Megha Tollefson, MD

                    Associate Professor of Dermatology and Pediatrics
                    Consultant, Dermatology
                    Consultant, Pediatric and Adolescent Medicine
                    Mayo Clinic Rochester

                      Wynnis Tom, MD

                      Clinical Professor of Dermatology and Pediatrics
                      Fellowship Program Director
                      Pediatric & Adolescent Dermatology
                      University of California, San Diego and Rady Children’s Hospital, San Diego

                        SPECIAL GUESTS

                        Emma Guttman-Yassky, MD, PhD

                        Vice Chair for Research
                        Incoming System Chair of the Kimberly and Eric J. Waldman Department of Dermatology
                        Icahn School of Medicine at Mount Sinai

                          Charlene Miciano

                          Charlene is a college student from San Diego majoring in bioinformatics. Her experience with eczema growing up influenced her to become an ambassador for the National Eczema Association. When she’s not coding, she enjoys music in many forms, whether it be playing piano or ukulele, doing karaoke, or going to concerts.

                            Korey Capozza, MPH

                            Korey is the founder and executive director of Global Parents for Eczema Research and the mother of a child with moderate to severe eczema. Her professional background is in public health, collaborative leadership, and patient-centered research.

                              Eric Simpson, MD

                              Professor of Dermatology
                              Oregon Health and Science University

                                Sarah Pry

                                Sarah is a mother of 2, Aiden age 12 and Bayle age 8. Aiden has severe eczema. Sarah works full time as an insurance agent in TN and in what spare time she has as a mom, she plays with her kids. She also loves to advocate and learn from the experts by volunteering or helping anyway that she can.

                                  Wendy Smith Begolka, MBS

                                  Ms. Smith Begolka is the VP for Scientific and Clinical Affairs for the National Eczema Association (NEA) where she guides the evolution and growth of NEA’s patient-centric research and clinical care efforts across the organization and with diverse stakeholders. Prior to joining NEA in 2018, she conducted biomedical laboratory research investigating immunological pathways of autoimmune disease at Northwestern University, and for over a decade, led the development of American Academy of Dermatology clinical guidelines and the application of science to the intersecting areas of quality, education, and advocacy. Her 25+ year scientific career has focused on advancing research, the use of scientific discovery and findings to support improved therapeutic options and clinical care, and the translation of research data for educational, quality, advocacy, and policy initiatives.

                                    Special thanks to Pfizer Inc. for their support of this independent medical education program.  PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.

                                    Webinar: From the NICU to Eczema and the Value of Research Funding

                                    By

                                    Tune in to hear Jennifer Schoch, MD from University of Florida discuss her research in the microbiome and eczema, and learn about the value of PeDRA funding.

                                    Jennifer Schoch, MD is Pediatric Dermatologist and Assistant Professor of Dermatology at the University of Florida. She is the recipient of a PeDRA Pilot Grant (2018), SPD/PeDRA Weston Career Development award (2019-20), PeDRA Shark Tank Award (2020-21) and an NIH KL2 Award (2020-22).

                                    Webinar: Hamartomas and midline anomalies in association with infantile hemangiomas, PHACE, and LUMBAR syndromes

                                    By

                                    Olivia Davies, MD Candidate and PeDRA Fellow discusses the findings of a recent publication – Hamartomas and midline anomalies in association with infantile hemangiomas, PHACE, and LUMBAR syndromes.

                                    Olivia Davies is a third year medical student at the Medical College of Wisconsin. She is currently the ’20-’21 PeDRA Fellow. Upon graduation from medical school, Olivia hopes to pursue a career in dermatology.

                                    Webinar: Clinical and Histologic Presentation of Pediatric Reactive Granulomatous Dermatitis

                                    By

                                    Lisa Arkin, MD presents the findings of a recent PeDRA study: Clinical and Histologic Presentation of Pediatric Reactive Granulomatous Dermatitis.

                                    Lisa Arkin, MD is the Director of Pediatric Dermatology and Assistant Professor of Dermatology at the University of Wisconsin, Madison. She has been a member of PeDRA since it’s inception and has served on several committees. She is the principal investigator for several PeDRA studies and was recently awarded a PeDRA Research grant to support her efforts in working towards a precision-based treatment for facial port wine birthmarks. She is currently the Chair of the Early Investigators Committee and oversees the annual EI Forum at the PeDRA Conference and PeDRA Research Mentorship Program.

                                    Webinar: Understanding Clinical Research

                                    By

                                    Co-founding PeDRA member, Anna Bruckner, MD, MSCS provides an overview of what clinical research is, how it works, who benefits, and why it’s important.

                                    Audio Only

                                    Anna L. Bruckner, MD, MSCS

                                    Dr. Bruckner is Associate Professor of Dermatology and Pediatrics and at the University of Colorado School of Medicine and Director of Pediatric Dermatology at Children’s Hospital Colorado. She attended Northwestern University as part of the Honors Program in Medical Education, earning her MD in 1997. She completed residencies pediatrics and dermatology at the University of Colorado followed by a fellowship in pediatric dermatology at the University of California San Francisco. She maintains board-certification in dermatology and pediatric dermatology.

                                    Dr. Bruckner is passionate about improving outcomes and quality of life for children with skin disorders through patient care, research, education and advocacy. Her academic interests include genetic skin disorders – particularly epidermolysis bullosa (EB), vascular anomalies, atopic dermatitis, and complex patients. She is the principal investigator for the Epidermolysis Bullosa Clinical Research Consortium, a network of North American EB care centers collaborating in clinic research aimed at improving the care and outcomes for patients with EB.

                                    Dr. Bruckner is a founding member of the Pediatric Dermatology Research Alliance, has served on the Executive Committee and is currently chairing PeDRA Studies Committee.